摘要
目的：评价A型肉毒杆菌毒素（BTX—A）治疗原发性三叉神经痛的疗效。方法：选取原发性三叉神经痛患者16例，于扳机点部位多点注射A型肉毒杆菌毒素，采用视觉模拟评分（VAS）和Barrow Neurological Institute（BNI）疼痛评价标准．在治疗前及治疗后1周、2周、1、3和6个月时进行疼痛测评。采用SPSS10．0软件包对数据进行统计学分析。结果：A型肉毒杆菌毒素注射治疗前VAS评分为（9．12±0．65）分，注射后1周、2周、1、3和6个月分别降至2．8±1．36、2．2±1．26、1．3±1．45、1．3±1．45和1．2±2．52分，与治疗前相比，差异均有显著性（P〈0．05）；1、3和6个月时，VAS评分较低且趋于稳定，但与1周、2周时相比，无显著差异修0．05）。16例患者均无明显全身并发症，2例治疗后1-2周出现不良反应，表现为右眼睑闭合无力和1：3角歪斜，未做任何处理，随着随访时间的延长，症状减轻，6个月时恢复正常，其余患者无任何不良反应。BNI疗效评价结果显示，治疗1周时已有较好疗效，1。3个月治疗效果最佳，6个月时复发1例．但仍有11例患者疼痛完全缓解。结论：A型肉毒杆菌毒素扳机点注射治疗原发性三叉神经痛是一种安全有效的新疗法。
PURPOSE：To investigate the effects of injection of botulium toxin type A at trigger point for treatment of patients with primary trigeminal neuralgia. METHODS ：Sixteen patients with primary Trigeminal Neuralgia were treated with injection of botulium toxin type A. Visual analog scores （VAS） at 1 week, 2 weeks, 1 month, 3months and 6 months after treatment and Barrow Neurological Institute （BNI） pain evaluation criteria were utilized to measure the degree of pain. The data was analyzed with SPSS 10.0 software package. RESULTS： The VAS score was 9.12±0.65 before botulium toxin type A injection while the scores were 2.8±1.36, 2.2±1.26, 1.3±1.45, 1.3±1.45 and 1.2±2.52 at 1 week, 2 weeks, 1 month, 3 months and 6 months after treatment. There was significant difference in VAS compared with before treatment. VAS score was lower and stable at 1 month, 3 months and 6 months after treatment, but no significant difference was found at 1-week and 2-week after treatment. BNI evaluation results showed good therapeutic effect 1 week after treatment, while the best therapeutic effect was noted 1-3 months after treatment. 6 months later, 1 patient had recurrence and 11 patients had complete relief of pain. CONCLUSIONS： Botulium toxin type A injection is an effective way for treatment of patients with primary trigeminal neuralgia.
出处
《上海口腔医学》
CAS
CSCD
北大核心
2014年第1期117-119,共3页
Shanghai Journal of Stomatology
关键词
A型肉毒毒素
三叉神经痛
注射治疗
Botulium toxin type A
Trigeminal neuralgia
Injection therapy
